Table 1.
Staging criteria for cutaneous T-cell lymphoma
| Stage | Clinical description | Tumor (T) | Node (N) | Metastasis (M) | Blood (B) |
|---|---|---|---|---|---|
| IA | Limited patch/plaque <10% | T1 | N0 | M0 | 0–1 |
| IB | Generalized patch/plaque >10% | T2 | N0 | M0 | 0–1 |
| IIA | Patch/plaque + adenopathy | T1–2 | N1–2 | M0 | 0–1 |
| IIB | Tumors ± adenopathy | T3 | N0–2 | M0 | 0–1 |
| III | Erythroderma ± adenopathy | T4 | N0–2 | M0 | 0–1 |
| IVA | Histologically + nodes or Sézary syndrome | T1–4 | N0–3 | M0 | 0–2 |
| IVB | Visceral involvement | T1–4 | N0–3 | M1 | 0–2 |
Notes: Adapted from Olsen E, Vonderheid E, Pimpinelli N, et al; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722. © 2007 by The American Society of Hematology.2